ArticleAntimicrobial agents and chemotherapy2004
Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Control of theJournal of bacteriology · 2025Article
- An analysis of the value-added of antibiogram subgroup stratification.Annals of clinical microbiology and antimicrobials · 2025Article
- Bismuth-based drugs sensitize Pseudomonas aeruginosa to multiple antibiotics by disrupting iron homeostasis.Nature microbiology · 2024Article
- Development of Biocompatible GaAntibiotics (Basel, Switzerland) · 2023Article
- Lipophilic Ga Complex with Broad-Spectrum Antimicrobial Activity and the Ability to Overcome Gallium Resistance in bothJournal of medicinal chemistry · 2021Article
- CCN1 is an opsonin for bacterial clearance and a direct activator of Toll-like receptor signaling.Nature communications · 2020Article
- Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections.Science translational medicine · 2018Article
- Quinolone-resistant clinical strains of3 Biotech · 2018Article
- Community acquired pneumonia among adult patients at an Egyptian university hospital: bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy.Infection and drug resistance · 2018Article
- Multidrug and vancomycin resistance among clinical isolates ofAfrican health sciences · 2017Article
- Aii810, a Novel Cold-AdaptedFrontiers in microbiology · 2017Article
- Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection.Scientific reports · 2016Article
- ESBL and MBL in Cefepime Resistant Pseudomonas aeruginosa: An Update from a Rural Area in Northern India.Journal of clinical and diagnostic research : JCDR · 2016Article
- Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay.Antimicrobial agents and chemotherapy · 2015Article
- Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model.Infection and immunity · 2014Article
- Multidrug-resistant bacterial isolates in infected wounds at Jimma University Specialized Hospital, Ethiopia.Annals of clinical microbiology and antimicrobials · 2013Article
- Activity of pyocin S2 against Pseudomonas aeruginosa biofilms.Antimicrobial agents and chemotherapy · 2012Article
- Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa.PloS one · 2012Article
- Hospital epidemiology and infection control in acute-care settings.Clinical microbiology reviews · 2011Review
- In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.Antimicrobial agents and chemotherapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the period from 1999 to 2002 in the United States, the in vitro susceptibilities of 52,637 Pseudomonas aeruginosa isolates to 10 antimicrobial agents were evaluated. The isolates were from 29 laboratories, 11 of which participated in The Surveillance Network for four consecutive years. Isolates were collected from adult patients (> or =18 years of age) in intensive care units (ICU), non-ICU inpatients, nursing home patients, and outpatients; data were analyzed to evaluate factors, such as year of isolation, patient age group, isolate specimen source, and patient type (hospitalized patients [ICU, non-ICU, or nursing home] or outpatients). Rates of resistance for the 4-year period were highest for isolates from patients in ICU and 18- to 39-year-old patients and for isolates from the lower respiratory tract. Resistance decreased with age. Resistance was lowest in isolates from outpatients, in isolates from > or =70-year-old patients, and from specimens from the upper respiratory tract. Multidrug resistance (MDR) (resistance to three or more antimicrobial agents) accounted for 24.9% of all isolates. The MDR rate was highest in isolates from patients in nursing homes (29.9%) and ICU (29.5%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.